HHyatt Hotels Corporation
The Read
Hyatt's stock historically reacted with a median 10% move on catalysts like earnings reports and travel demand data, but faced sharper declines when confronted with governance risks and weak macro trends.
The schedule
- Thu15Oct
Travel demand analysis during Labor Day holiday period
- Thu5Nov
Quarterly earnings report with updated 2026 guidance
- Thu31Dec
Annual performance review and forward-looking guidance
- Tue9Feb
- Thu6May
- Thu5Aug
Past
- Tue15Sep
STR data release and corporate performance review post-summer travel season
- Thu30Apr
Actual outcome: Bull · $170.47 at outcome
Hyatt delivered a strong Q1 2026 earnings beat, reporting EPS of $0.63 against estimates of $0.57, driven by higher fees and a 5.4% increase in comparable system-wide RevPAR. The company also raised its full-year 2026 outlook and accelerated share buybacks, signaling confidence in sustained demand and margin strength. These robust fundamental results and positive forward guidance propelled the stock well past the $165 bull target.
- Sun1Mar
Actual outcome: Bear · $139.95 at outcome
Hyatt's stock fell significantly below the $165.00 bear floor to $139.30 as persistent industry headwinds and a legal investigation into potential breaches of fiduciary duties by directors overshadowed travel demand data. While the company highlighted loyalty gains at investor conferences, the combination of macro worries and corporate governance concerns triggered a sharp decline in valuation following the spring travel window.
- Fri13Feb
Actual outcome: Bull · $165.39 at outcome
The company reported Q4 EPS of -$0.21, exactly matching consensus estimates. While the immediate price reaction was flat, constructive 2026 forward guidance reassured investors about the company's long-term trajectory. This stabilization in fundamentals ultimately fueled a sustained rally, driving the stock well beyond the $168.00 bull target in the subsequent months.
Scouting Reports
The Passive Tax: How SPGI and NDAQ Monetize Silicon Concentration
Oct 13, 2026
The headline equity benchmark is up 14% this year, yet beneath the surface, more than four in ten S&P 500 constituents are actively underwater. The broader U.S. economy is not necessarily booming; rat
Read more →
The $700B Capex Wall: Testing Tech's Immunity to 5.3% Yields
Oct 6, 2026
Monday's price action delivered a textbook contradiction. The Nasdaq Composite sailed to a record 27,477 and NVDA printed fresh all-time highs, right alongside the 10-year Treasury yield surging past
Read more →
Weekly Playbook: Pricing the Healthcare Gauntlet (ABEO, LFVN, KROS)
Oct 5, 2026
The healthcare and biotech sectors are defined by their bottlenecks. Whether a company is waiting on federal guidance or fighting to clear a clinical hurdle, the market brutally penalizes any friction
Read more →